Founded Date: 2008
Last Funding Type: Post-IPO Equity
Headquarters: Oxton, York, United Kingdom
Investors Number: 14
Technology: P4 Medicine
Employee Number: 51-100
Industry: Genomic and Epigenominc Instabillity
Estimated Revenue: Less than $1M
Number Of Exists: Post-IPO Equity
Funding Status: IPO
Investor Type: Company
Investment Stage: N/A
Total Funding: $249.5M